Cardinal Health
CAH
232.16
-1.28
-0.55%
Cardinal Health
US · CAH
#429 by market cap
Listed 1970
232.16
-1.28
-0.55%
Live - 5344 symbols - heartbeat 58s ago
· 2026-10-08 07:00
Pre-market
227.75
-1.90%
After-hours
232.90
+0.32%
- Market cap
- 53.76B
- P/E (TTM)i
- 32.11
- P/Bi
- -18.65
- EPSi
- 7.23
- Div yieldi
- 0.88%
- 52W posi
- 76%
Reader sentiment
Are you bullish or bearish on CAH?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Accumulating
- The number of reporting institutions decreased by 7 in the most recent period (2026/Q3).
- Total institutional ownership rose 0.4 percentage points.
Institutional ownership
- Held by institutions
- 91.01% +0.43pp
- Institutions
- 1,758 -7
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
DivergingInstitutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund74.91%
Public Company4.74%
Hedge Fund3.37%
Private Company3.14%
Government Pension Fund2.22%
Sovereign Wealth Fund1.68%
Family Office/Trust0.31%
Insurance Company0.30%
Corporate Pension Plan0.14%
Other9.19%
Top holders
BlackRock
11.44%
Vanguard Capital Management, LLC
7.18%
Wellington Management Group
6.42%
Vanguard Portfolio Management, LLC
5.92%
State Street Global Advisors
5.17%
Geode Capital Management, LLC
2.80%
WCM Investment Management
1.78%
Norges Bank Investment Management
1.61%
UBS Asset Management
1.36%
Morgan Stanley
1.24%
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 26 buys · 24 sells
| Name | Role | Stake |
|---|---|---|
| Jason Hollar | Chief Executive Officer | 0.05% |
| Deborah Weitzman | Chief Executive Officer of Pharmaceutical Segment | 0.03% |
| Stephen Mason | Chief Executive Officer of Medical segment | 0.01% |
| Jessica Mayer | Chief Legal & Compliance Officer | 0.01% |
| Ola Snow | Chief Human Resources Officer | 0.01% |
| Patricia Hemingway Hall | Independent Director | 0.00% |
| Michelle Greene | Executive VP, Chief Information Officer & Customer Support Services | 0.00% |
| Michelle Brennan | Independent Director | 0.00% |
| Valerie Pitteroff | Chief Human Resources Officer | 0.00% |
| Sheri Edison | Independent Director | 0.00% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-08-18 | Jason Hollar | Chief Executive Officer | Open Market Disposition | -124,529 | $233.22–237.88 |
| 2026-08-18 | Mary Scherer | Chief Accounting Officer | Open Market Disposition | -2,302 | $237.39–237.40 |
| 2026-08-17 | Aaron Alt | Chief Financial Officer | Open Market Disposition | -42,000 | $234.55–237.26 |
| 2026-08-17 | Deborah Weitzman | Chief Executive Officer of Pharmaceutical Segment | Open Market Disposition | -7,354 | $235.30–237.44 |
| 2026-08-17 | Jessica Mayer | Chief Legal & Compliance Officer | Open Market Disposition | -29,436 | $234.64–237.31 |
| 2026-08-17 | Stephen Mason | Chief Executive Officer of Medical segment | Open Market Disposition | -35,000 | $234.59–237.26 |
| 2026-08-17 | Michelle Greene | Executive VP, Chief Information Officer & Customer Support Services | Open Market Disposition | -11,650 | $234.57–237.25 |
| 2026-08-14 | Jason Hollar | Chief Executive Officer | Sale to Issuer | -103,449 | $235.17 |
| 2026-08-14 | Jason Hollar | Chief Executive Officer | Other Acquisition | +30,616 | -- |
| 2026-08-14 | Aaron Alt | Chief Financial Officer | Sale to Issuer | -30,730 | $235.17 |
| 2026-08-14 | Aaron Alt | Chief Financial Officer | Other Acquisition | +8,079 | -- |
| 2026-08-14 | Deborah Weitzman | Chief Executive Officer of Pharmaceutical Segment | Sale to Issuer | -29,759 | $235.17 |
| 2026-08-14 | Deborah Weitzman | Chief Executive Officer of Pharmaceutical Segment | Other Acquisition | +7,314 | -- |
| 2026-08-14 | Jessica Mayer | Chief Legal & Compliance Officer | Sale to Issuer | -25,285 | $235.17 |
| 2026-08-14 | Jessica Mayer | Chief Legal & Compliance Officer | Other Acquisition | +6,378 | -- |
| 2026-08-14 | Stephen Mason | Chief Executive Officer of Medical segment | Sale to Issuer | -25,289 | $235.17 |
| 2026-08-14 | Stephen Mason | Chief Executive Officer of Medical segment | Other Acquisition | +5,868 | -- |
| 2026-08-14 | Michelle Greene | Executive VP, Chief Information Officer & Customer Support Services | Sale to Issuer | -10,031 | $235.17 |
| 2026-08-14 | Michelle Greene | Executive VP, Chief Information Officer & Customer Support Services | Other Acquisition | +2,551 | -- |
| 2026-08-14 | Mary Scherer | Chief Accounting Officer | Sale to Issuer | -1,757 | $235.17 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 07:00:05 · For reference only, not investment advice and not tailored to your situation.